An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: NewYork–Presbyterian Hospital, Cornell University, The University of Texas MD Anderson Cancer Center, AZ Sint-Jan, Hospital Universitari i Politècnic La Fe, The Alfred Hospital, Helsinki University Hospital, Instituto Português de Oncologia Francisco Gentil, Vanderbilt University Medical Center, Hospital Universitario Virgen del Rocío, Università Cattolica del Sacro Cuore, Celgene (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600516765